Pilot Project Of Horizon Scanning To Inform The Ukrainian Health System About New HIV/AIDS Health Technologies - Pilot - key findings

Sep 29, 2026

Uploaded by Noah

The pilot project implemented horizon scanning to proactively inform Ukraine’s health system about new HIV/AIDS health technologies and to evaluate prospects for using the horizon scanning tool domestically. Conducted at Ukraine’s State Expert Centre under the Ministry of Health, it tested core horizon scanning methods and the PRITECTOOLS prioritization tool using a dataset from international and local sources, including trials, patents, publications, early assessments, media, and organization websites. The team identified relevant new medicines including cabotegravir, an ibalizumab-based option, and a dapivirine vaginal ring. The results indicate the tool can support prevention, diagnosis, and treatment decisions and serve as an HTA process stage.

LanguageEnglish

CategoryHealthcare

FormatPDF

Pages1

Reading Time3 min

AccessFree to download

Introduction

Methods

Results

Conclusions

PD64 Cost-Minimization Analysis And Psoriatic Arthritis: Insights From Health Technology Assessment Agency Recommendations Hérica Núbia Cardoso Cirilo, Aldenora Maria Ximenes Rodrigues, Ana Carolina Peçanha Antonio, Bruna Santos ([brunabentods@gmail.com](brunabentods@gmail.com)), Cecília de Oliveira Carvalho Faria, Alicia Dornelles and Ida Schwartz Introduction: Health technology assessment (HTA) bodies published stringent criteria for cost-minimization analyses (CMA), but evidence shows that many appraisals still fail to meet their full requirements: notably, adequately powered trials showing noninferior outcomes regarding minimal clinically important difference. Here, we report the use ofCMA in recommending biological diseasemodifying antirheumatic drugs (bDMARDs) in psoriatic arthritis. Methods: A comprehensive review of HTA agency reports was conducted to identify the economic evaluations applied in the appraisal of bDMARDs for psoriatic arthritis. Data were collected from publicly available HTA databases and official websites of globally recognized agencies. The search included appraisals published up to December 2024 . Evaluations were categorized based on the economic model used (e.g., CMA, cost effectiveness, cost utility, or cost benefit) . Extracted data were analyzed to summarize trendsand identify differences in the economic approaches used among agencies. Results: Cost-effectiveness and cost-utility analyses were the predominant approaches in HTA agency assessments of bDMARDs for psoriatic arthritis. Certolizumab pegol, golimumab, and secukinumab were the most frequently evaluated medications, each with nine evaluations. The Brazilian National National Committee for Health Technology Incorporation (CONITEC) was the only agency that exclusively used CMA in all its evaluations. In contrast, the National Institute for Health and Care Excellence (NICE) did not use this methodology in its assessments. Conclusions: Our findings highlight the significant variation in economic evaluation methods used by HTA agencies for bDMARDsin psoriatic arthritis. The inappropriateness of superiority trials that fail to reject the null hypothesis for CMA is a key takeaway. While CMA remain relevant due to their simplicity, their use by CONITEC contrasts with broader methodologies preferred by other agencies, particularly NICE. PD65 Pilot Project Of Horizon Scanning To Inform The Ukrainian Health System About New HIV/AIDS Health Technologies Oresta Piniazhko, Elizaveta Otrubchak ([elizavetaotrubcak@gmail.com](elizavetaotrubcak@gmail.com)), Tamara Mahanova, Iryna Musiienko, Valeriia Serediuk, Iuliia Malyshevska, Iñaki Gutiérrez Ibarluzea, Mykhaylo Babenko, Mykhailo Lobas, Olena Filiniuk, Taras Lyaskovskyi and Rabia Sucu Introduction: Horizon scanning is an advanced health technology assessment (HTA) tool integrated into the decision-making process to proactively inform stakeholders about new health technologies. The objective of this pilot was to conduct horizon scanning for new health technologies for HIV/AIDS that could be appropriate for Ukraine’s health system, and to assess prospects for using the horizon scanning tool in Ukraine. Methods: The pilot project was conducted at the State Expert Centre of the Ministry of Health in Ukraine. The pilot project tested the basic horizon scanning methodology as well as the PRITECTOOLS prioritization tool using a dataset compiled from international and local databases of clinical trials, patents, academic publications, international horizon scanning and early assessment databases, media resources (including online resources), and websites of public and charitable organizations. Results: The team identified the following new medicines that maybe relevant for Ukraine: cabotegravir (long-acting injectable integrase strand transfer inhibitor—an alternative to tablet-based regimens for daily pre-exposure prophylaxis to increase patient adherence); ibali[zumab. an](zumab. an) in

FAQs

What is the purpose of the horizon scanning pilot project?

To conduct horizon scanning for new HIV/AIDS health technologies suitable for Ukraine’s health system and to assess the prospects for using the horizon scanning tool in Ukraine.

How was the pilot carried out and what tools were tested?

It was conducted at Ukraine’s State Expert Centre of the Ministry of Health and tested the basic horizon scanning methodology as well as the PRITECTOOLS prioritization tool.

Which new HIV/AIDS medicines were identified as potentially relevant?

The team identified cabotegravir, an ibalizumab-based injectable option for multidrug-resistant HIV-1, and a dapivirine vaginal ring to reduce HIV-1 infection risk in women during sexual intercourse.

What value does the horizon scanning tool add for Ukraine’s health system and HTA?

It can inform prevention, diagnosis, and treatment and can be used as one stage in Ukraine’s HTA process to help decision-makers proactively anticipate and plan for assessments of priority conditions.

Sep 29, 2026

Uploaded by Noah